Bibliography
- Di Lorenzo G, Casciano R, Malangone E, et al. Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother 2012;13(7):1079-80
- Hoaglin DC, Cislo R. Letter to the Editor: An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma − a flawed analysis? Expert Opin Pharmacother 2012;13(7):1077-8
- Di Lorenzo G, Casciano R, Malangone E, et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother 2011;12(10):1491-7
- Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
- Gartlehner G, Moore CG. Direct versus indirect comparisons: a summary of the evidence. Int J Technol Assess Health Care 2008;24(2):170-7
- Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 2010;28(10):935-45